Angiotech reports success with drug-coated catheter

10/10/2007 | Boston Globe (tiered subscription model), The

Device firm Angiotech Pharmaceuticals said it plans to file a premarket notification with the FDA for its 5-Fluorouracil-coated Central Venous Catheter after positive clinical trial results. The company said the 5-FU drug is intended to prevent bacterial growth in implanted catheters.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD